<DOC>
	<DOCNO>NCT01323270</DOCNO>
	<brief_summary>This study look new vaccine might prevent meningococcal disease , look safety new vaccine well tolerate give together Repevax . The study do healthy adolescent .</brief_summary>
	<brief_title>A Trial Assess Safety , Tolerability Immunogenicity Repevax rLP2086 Vaccine When Given Together Healthy Subjects Aged &gt; =11 &lt; 19 Years .</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<criteria>Evidence personally sign date informed consent document indicate parent/legally acceptable representative and/or subject inform pertinent aspect study . Parent/legally acceptable representative and/or subject willing able comply schedule visit , laboratory test , study procedure . Male female subject age â‰¥11 &lt; 19 year time enrollment . Available entire study period reach telephone . Healthy subject determine medical history , physical examination , judgment investigator . Has receive full series diphtheria , tetanus , pertussis ( DTP ) /DTaP vaccine oral poliomyelitis virus ( OPV ) /IPV vaccine per countryspecific recommendation applicable time receipt . All male female subject must agree practice form effective contraception , barrier contraception ( ie , condom plus spermicide , female condom , diaphragm , cervical cap intrauterine device ) , implant , injectables , combine oral contraceptive sexual abstinence prior enter study , duration vaccination period 28 day last study vaccination . For Germany : The phrase sexual abstinence applicable , understanding male female subject childbearing potential must practice effective form contraception study . Negative urine pregnancy test female subject . Previous vaccination meningococcal serogroup B vaccine . Vaccination diphtheria , tetanus , pertussis , poliomyelitis virus vaccine within 5 year first study vaccination . A previous anaphylactic reaction vaccine vaccinerelated component . Contraindication vaccination diphtheria , tetanus , pertussis , poliomyelitis virus vaccine . Bleeding diathesis condition associate prolonged bleeding time would contraindicate intramuscular injection . A know suspected disease immune system receive immunosuppressive therapy . History cultureproven disease cause Neisseria meningitidis Neisseria gonorrhoeae . Significant neurological disorder history seizure ( exclude simple febrile seizure ) . Receipt blood product , include immunoglobulin within 6 month first study vaccination . Current chronic use systemic antibiotic . Participation study study participation . Participation purely observational study acceptable . Received investigational drug , vaccine device within 28 day administration first study vaccination . Any neuroinflammatory autoimmune condition , include , limited , transverse myelitis , uveitis , optic neuritis , multiple sclerosis . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study . Subjects investigational site staff member subject Pfizer employee directly involve conduct trial . Subject direct descendant ( eg , child , grandchild family member ) study site Pfizer personnel . Subject pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>11 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Healthy adolescent</keyword>
</DOC>